Preventive therapy for breast cancer

Current Oncology Reports

Volumn 14, Issue 6, 2012, Pages 568-573

  Sestak, Ivana ^a   Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast cancer; Preventive therapy; Selective oestrogen receptor modulators

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; ARZOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LASOFOXIFENE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; CORONARY ARTERY DISEASE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FRACTURE; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; INTRADUCTAL CARCINOMA; MUSCLE CRAMP; OSTEOPOROSIS; POSTMENOPAUSE; RISK REDUCTION; SPINE FRACTURE; THROMBOEMBOLISM; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; MIDDLE AGED; PIPERIDINES; PREVENTIVE MEDICINE; PYRROLIDINES; RALOXIFENE; RECEPTOR, ERBB-2; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84870541493     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0273-5     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388-98.
3. Tseng M, Weinberg CR, Umbach DM, Longnecker MP. Calculation of population attributable risk for alcohol and breast cancer (United States). Cancer Causes Control. 1999;10(2):119-23.
4. Sestak I, Cuzick J. Breast cancer chemoprevention. Oncol Rev. 2008;2:221-6.
5. Wiseman H. Tamoxifen: Molecular basis of use in cancer treatment and prevention. 1st ed. Chichester: John Wiley & Sons Ltd; 1994.
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-67.
7. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296-300.
8. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2(8449):282.
9. Jordan C., Tamoxifen for the prevention of breast cancer, De Vita, Editor. 1990, Cancer Prevention. p. 1-12.
10. Cuzick J, Wang DY, Bulbrook RD. The prevention of breast cancer. Lancet. 1986;1(8472):83-6.
11. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352(9122):98-101.
12. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99 (4):283-90.
13. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360 (9336):817-24.
14. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-82.
15. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99 (9):727-37.
16. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet. 2002;359(9312):1122-4.
17. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-62.
18. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-88.
19. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352(9122):93-7.
20. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama. 1999;281(23):2189-97.
21. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751-61.
22. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125-37.
23. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. Jama, 2006.
24. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM,et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 362(8): p. 686-96.
25. Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 26(2): p. 397-404.
26. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-9.
27. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23(22):5138-47.
28. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486-92.
29. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-92.
30. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-802.
31. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455-62.
32. Mamounas E, Jeong JH, Wickerham DL, Smith R, Geyer C, Ganz P, et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): Intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat. 2006;100(Supplemnt 1):S22.
33. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802-10.
34. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.
35. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.
36. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28 (3):509-18.
37. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364 (25):2381-91.
38. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005;5:159.
39. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2006;6:27.
40. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer. 2006;94(3):346-50.
41. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med. 2005;165(19):2264-71.
42. Esserman LJ, Campbell M and Shoemaker M. Breast cancer inhibition by statins. in ASCO. 2004: Proc. Am. Soc. Clin. Oncol.
43. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011;103(9):744-52.
44. Kim J, HanW, Moon HG, Ahn SK, Shin HC, You JM, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res. 2012;14(4):R102.